New combo therapy tested for Tough-to-Treat lymphomas
NCT ID NCT02446457
Summary
This study is testing whether combining the immunotherapy drug pembrolizumab with the standard antibody rituximab (with or without the drug lenalidomide) can help control lymphoma that has come back after previous treatment. It is for adults with specific types of B-cell lymphoma whose cancer has returned. The main goal is to see how many patients' cancers shrink in response to these drug combinations.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.